Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 2/2011

01-04-2011 | Current Opinion

Ozone: A New Therapeutic Agent in Vascular Diseases

Authors: Velio Bocci, MD, Iacopo Zanardi, Valter Travagli, PharmD

Published in: American Journal of Cardiovascular Drugs | Issue 2/2011

Login to get access

Abstract

In this article, we scientifically evaluate the bio-oxidative procedure known as oxygen-ozone therapy. Research over a decade has established a comprehensive framework for understanding and recommending this type of autohemotherapy in vascular diseases. In contrast, a non-specific immunomodulation therapy, using heavily oxidized and denatured blood, has been recently used in studies involving a total of approximately 3000 patients and has led to ‘disappointing’ results. Such a treatment appears to be an inappropriate example of the so-called minor autohemotherapy, and its poor outcomes may discourage any further studies. Therefore it appears necessary to clarify that the use of only a minimal ozone dose and a valid experimental protocol is likely to produce beneficial results. Millions of people suffer from chronic limb, brain, and heart ischemia, and such patients may benefit if appropriate ozone therapy could be implemented. Accordingly, we propose the need for a well designed, multicenter, clinical trial to be conducted.
Literature
1.
Nakao A, Sugimoto R, Billiar TR, et al. Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009; 44: 1–13.PubMedCrossRef
2.
Rokitanski O, Rokitanski A, Steiner J, et al. Die ozontherapie bei peripheren, arteriellen Durchblutungs-strörugen; linik, biochemische und blutgasanalytische untersuchungen. Wasser IOA, Ozon-Weltkongress; Berlin, 1981: 53–75.
3.
Matassi R, D’Angelo F, Bisetti P, et al. Terapia con ozono per via parenterale nelle arteropatie obliteranti periferiche: meccanismo biochimico e risultati clinici. Il Giornale di Chirurgia 1987; VIII: 109–11.
4.
De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med 2005; 11: 363–7.PubMedCrossRef
5.
Hernandez F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 1995; 19: 115–9.PubMedCrossRef
6.
Biedunkiewicz B, Tylicki L, Nieweglowski T, et al. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygen controlled study. Int J Artif Organs 2004; 27: 29–34.PubMed
7.
Di Paolo N, Bocci V, Garosi G, et al. Extracorporeal blood oxygenation and ozonation (EBOO) in man: preliminary report. Int J Artif Organs 2000; 23: 131–41.PubMed
8.
Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs 2005; 28: 1039–50.PubMed
9.
Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebocontrolled randomised trial. Lancet 2008; 371: 228–36.PubMedCrossRef
10.
Travagli V, Zanardi I, Bernini P, et al. Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol 2010; 29: 165–74.PubMedCrossRef
11.
12.
Pryor WA. Mechanisms of radical formation from reactions of ozone with target molecules in the lung. Free Radic Biol Med 1994; 17: 451–65.PubMedCrossRef
13.
Tager IB, Balmes J, Lurmann F, et al. Chronic exposure to ambient ozone and lung function in young adults. Epidemiology 2005; 16: 751–9.PubMedCrossRef
14.
Ruidavets JB, Cournot M, Cassadou S, et al. Ozone air pollution is associated with acute myocardial infarction. Circulation 2005; 111: 563–9.PubMedCrossRef
15.
16.
Jerrett M, Burnett RT, Pope 3rd CA, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360: 1085–95.PubMedCrossRef
17.
Bastacky J, Lee CYC, Goerke J, et al. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J Appl Physiol 1995; 79: 1615–28.PubMed
18.
Cho HY, Zhang LY, Kleeberger SR. Ozone-induced lung inflammation and hyperreactivity are mediated via tumor necrosis factor-alpha receptors. Am J Physiol Lung Cell Mol Physiol 2001; 280: L537–46.PubMed
19.
Last JA, Gohil K, Mathrani VC, et al. Systemic responses to inhaled ozone in mice: cachexia and down-regulation of liver xenobiotic metabolizing genes. Toxicol Appl Pharmacol 2005; 208: 117–26.PubMedCrossRef
20.
Uppu RM, Cueto R, Squadrito GL, et al. What does ozone react with at the air/lung interface? Model studies using human red blood cell membranes. Arch Biochem Biophys 1995; 319: 257–66.PubMedCrossRef
21.
Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 2006; 216: 493–504.PubMedCrossRef
22.
Search strategy used to create CAM on PubMed (PubMed’s Complementary Medicine Subset) [online]. Available from URL: http: //www.nlm.nih.gov/ bsd/pubmed_subsets/comp_med_strategy.html [Accessed 2010 Mar 2].
23.
Forman HJ. Hydrogen peroxide: the good, the bad and the ugly. In: Valacchi G, Davis P, editors. Oxidants in biology. Dordrecht: Springer, 2008: 1–17.CrossRef
24.
Barrera G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med 2008; 29: 1–8.PubMedCrossRef
25.
Yang G, Wu L, Jiang B, et al. H2 S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587–90.PubMedCrossRef
26.
Long EK, Picklo Sr MJ. Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med 2010; doi: 10.1016/j. Epub.
27.
Bocci V, Borrelli E, Travagli V, et al. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009; 29: 646–82.PubMedCrossRef
28.
Battino R, Rettici TR, Tominaga T. The solubility of oxygen and ozone in liquids. J Phys Chem Ref Data 1983; 12: 163–78.CrossRef
29.
Pryor WA, Squadrito GL, Friedman M. The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radical Biol Med 1995; 19: 935–41.CrossRef
30.
Bocci V. Ozone: a new medical drug. 2nd ed. Dordrecht: Springer Science, 2011.
31.
Bocci V. Scientific and medical aspects of ozone therapy: state of the art. Arch Med Res 2006; 37: 425–35.PubMedCrossRef
32.
Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol 2006; 20: 133–8.PubMedCrossRef
33.
Travagli V, Zanardi I, Silvietti A, et al. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41: 504–11.PubMedCrossRef
34.
Bocci V, Zanardi I, Michaeli D, et al. Mechanisms of action and chemicalbiological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Curr Drug Ther 2009; 4: 159–73.CrossRef
35.
Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents 1998; 12: 67–75.
36.
Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm 1998; 7: 313–7.
37.
Shinriki N, Suzuki T, Takama K, et al. Susceptibilities of plasma antioxidants and erythrocyte constituents to low levels of ozone. Haematologia 1998; 29: 229–39.PubMed
38.
Carballal S, Alvarez B, Turell L, et al. Sulfenic acid in human serum albumin. Amino Acids 2007; 32: 543–51.PubMedCrossRef
39.
Aldini G, Vistoli G, Regazzoni L, et al. Albumin is the main nucleophilic target of human plasma: a protective role against proatherogenic electrophilic reactive carbonyl species? Chem Res Toxicol 2008; 21: 824–35.PubMedCrossRef
40.
Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. Free Radic Biol Med 1998; 25: 221–8.PubMedCrossRef
41.
Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999; 31: 261–72.PubMedCrossRef
42.
Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997; 38: 79–101.PubMedCrossRef
43.
Antunes F, Cadenas E. Estimation of H2 O2 gradients across biomembranes. FEBS Lett 2000; 475: 121–6.PubMedCrossRef
44.
Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243–70.PubMedCrossRef
45.
Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12.PubMed
46.
Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediat Inflamm 2000; 9: 271–6.CrossRef
47.
Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141–79.PubMedCrossRef
48.
Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediat Inflamm 1999; 8: 205–9.CrossRef
49.
Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenalmediated signaling by glutathione S-transferase. Methods Enzymol 2005; 401: 379–407.PubMedCrossRef
50.
51.
Petras T, Siems WG, Grune T. 4-Hydroxynonenal is degraded to mercapturic acid conjugate in rat kidney. Free Radic Biol Med 1995; 19: 685–8.PubMedCrossRef
52.
Poli G, Schaur RJ, Siems WG, et al. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev 2008; 28: 569–631.PubMedCrossRef
53.
Takahashi Y, Takahashi S, Yoshimi T, et al. Increases in the mRNA levels of γ-glutamyltransferase and heme oxygenase-1 in the rat lung after ozone exposure. Biochem Pharmacol 1997; 53: 1061–4.PubMedCrossRef
54.
55.
Cheng JZ, Sharma R, Yang Y, et al. Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress. J Biol Chem 2001; 276: 41213–23.PubMedCrossRef
56.
Yang YS, Sharma R, Sharma A, et al. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 2003; 50: 319–36.PubMed
57.
Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004; 37: 937–45.PubMedCrossRef
58.
Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med 2003; 24: 167–75.PubMedCrossRef
59.
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42.PubMed
60.
Hobbs AJ. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 1997; 18: 484–91.PubMed
61.
Wang R. Two’s company, three’s a crowd: can H2 S be the third endogenous gaseous transmitter? FASEB J 2002; 16: 1792–8.PubMedCrossRef
62.
Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radical. Nat Med 2007; 13: 688–94.PubMedCrossRef
63.
64.
Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 2010; 29: 249–61.PubMedCrossRef
65.
Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it “remembered wellness”. Annu Rev Med 1996; 47: 193–9.PubMedCrossRef
66.
Schulz S, Häussier U, Mandic R, et al. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer 2008; 122: 2360–7.PubMedCrossRef
67.
Viru A, Tendzegolskis Z. Plasma endorphin species during dynamic exercise in humans. Clin Physiol 1995; 15: 73–9.PubMedCrossRef
68.
Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. Exp Biol Med 1967; 126: 356–8.
69.
Bocci V, Borrelli E, Valacchi G, et al. Quasi-total-body exposure to an oxygenozone mixture in a sauna cabin. Eur J Appl Physiol Occup Physiol 1999; 80: 549–54.PubMedCrossRef
70.
Bocci V, Zanardi I, Travagli V, et al. Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device. Artif Organs 2007; 31: 743–8.PubMedCrossRef
71.
Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79–127.PubMedCrossRef
72.
Jacobs MT. Untersuchung uber zwishenfalle und typische komplikationen in der ozon-sauerstofftherapie. OzoNachrichten 1982; 5: 1–5.
73.
Allegra C, Antignani PL, Schachter I, et al. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Ann Vasc Surg 2008; 22: 552–8.PubMedCrossRef
74.
Tylicki L, NiewgŁowski T, Biedunkiewicz B, et al. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs: pilot study. Int J Artif Organs 2001; 24: 79–82.PubMed
75.
Tylicki L, Nieweglowski T, Biedunkiewicz B, et al. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int J Artif Organs 2003; 26: 297–303.PubMed
76.
Tylicki L, Biedunkiewicz B, Nieweglowski T, et al. Ozonated autohemotherapy in patients on maintenance hemodialysis: influence on lipid profile and endothelium. Artif Organs 2004; 28: 234–7.PubMedCrossRef
77.
Bulmer J, Bolton AE, Pockley AG. Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations. J Biol Regul Homeost Agents 1997; 11: 104–10.PubMed
78.
Bocci V, Travagli V, Zanardi I. Maybe oxygen-ozone therapy blocks the progression of cardiovascular disorders? Cardiovasc Hematol Disord Drug Targets 2009; 9: 78–85.PubMedCrossRef
79.
Garber GE, Cameron DW, Hawley-Foss N, et al. The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS 1991; 5: 981–4.PubMedCrossRef
80.
Hooker MH, Gazzard BG. Ozone-treated blood in the treatment of HIV infection [letter]. AIDS 1992; 6: 131.PubMedCrossRef
81.
Olin JW. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial diseases: the SIMPADICO trial. Smaller Late-Breaking Clinical Trials I, American College of Cardiology 55th Annual Scientific Sessions; 2006 Mar 11–14; Atlanta (GA).
82.
Torre-Amione G, Sestier F, Radovancevic B, et al. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44: 1181–6.PubMedCrossRef
83.
Sliwa K, Ansari AA. Immunosuppression as therapy for congestive heart failure. Lancet 2008; 371: 184–6.PubMedCrossRef
84.
85.
Bocci V. The failure of the ACCLAIM trial is due to an irrational technology. Int J Cardiol 2010; 139: 304–5.PubMedCrossRef
86.
Bocci V, Zanardi I, Travagli V. The irrationality of a non-specific immunomodulation therapy used in cardiovascular diseases deserves a critical comment. Atherosclerosis 2010; 211: 38–9.PubMedCrossRef
87.
Bocci V, Aldinucci C, Mosci F, et al. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm 2007; 26785. doi: 10.1155/2007/26785.
88.
Di Filippo C, Luongo M, Marfella R, et al. Oxygen/ozone protects the heart from acute myocardial infarction through local increase of eNOS activity and endothelial progenitor cells recruitment. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 287–91.PubMedCrossRef
Metadata
Title
Ozone: A New Therapeutic Agent in Vascular Diseases
Authors
Velio Bocci, MD
Iacopo Zanardi
Valter Travagli, PharmD
Publication date
01-04-2011
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 2/2011
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/11539890-000000000-00000

Other articles of this Issue 2/2011

American Journal of Cardiovascular Drugs 2/2011 Go to the issue

Original Research Article

Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus

Short Communication

Acute Effects of Tobacco Chewing on the Systemic, Pulmonary and Coronary Circulation

Therapy In Practice

Therapy of Hypertension in African Americans

Adis R&D Profile

Edoxaban Tosylate

Review Article

Are All Statins the Same?

Adis R&D Profile

Varespladib